scispace - formally typeset
M

Maria Maryanovich

Researcher at Albert Einstein College of Medicine

Publications -  23
Citations -  932

Maria Maryanovich is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Stem cell & Bone marrow. The author has an hindex of 8, co-authored 19 publications receiving 589 citations.

Papers
More filters
Journal ArticleDOI

Adrenergic nerves activate an angio-metabolic switch in prostate cancer

TL;DR: Studying mouse models of prostate cancer, it is shown that endothelial β-adrenergic receptor signaling via adrenergic nerve–derived noradrenaline in the prostate stroma is critical for activation of an angiogenic switch that fuels exponential tumor growth.
Journal ArticleDOI

Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche.

TL;DR: It is shown that HSC aging critically depends on bone marrow innervation by the sympathetic nervous system (SNS), as loss of SNS nerves or adrenoreceptor β3 signaling in the bone marrow microenvironment of young mice led to premature HSC Aging, as evidenced by appearance of HSC phenotypes reminiscent of physiological aging.
Journal ArticleDOI

Neural Regulation of Hematopoiesis, Inflammation, and Cancer

TL;DR: The importance of neural signaling in hematopoietic homeostasis, inflammation, and cancer is reviewed and the need to redesign therapeutic strategies to target this underappreciated stromal constituent is outlined.
Journal ArticleDOI

Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cells.

TL;DR: Five transcriptional regulators are identified that can revitalize Nestin-expressing mesenchymal stromal cells to enhance the synthesis of haematopoietic stem cell niche factors, improve haemorrhaging stem cell expansion and protect them against DNA damage.
Journal ArticleDOI

Neural Regulation of Bone and Bone Marrow.

TL;DR: The interplay of the nervous system with bone, BM, and immunity is reviewed, and future challenges to target hematological diseases through modulation of activity ofThe nervous system are discussed.